Table 1.
Demographics of 1,165 oncology patients aged 15–39 years by treatment modality
| Anthracycline only | VEGF inhibitor only | Anthracycline and VEGF inhibitor (N = 74) | |||||
|---|---|---|---|---|---|---|---|
| (N = 891) | (N = 200) | ||||||
| N | (%) | N | (%) | N | (%) | p | |
| Sex, n (%) | 0.33 | ||||||
| Male | 443 | (50) | 88 | (44) | 35 | (47) | |
| Female | 448 | (50) | 112 | (56) | 39 | (53) | |
| Race, n (%) | 0.16 | ||||||
| White | 716 | (80) | 163 | (82) | 64 | (86) | |
| Black | 142 | (16) | 25 | (13) | 7 | (9) | |
| Other | 33 | (4) | 11 | (6) | 3 | (4) | |
| Unknown | 0 | (0) | 1 | (0) | 0 | (0) | |
| Age at first treatment (y; median, IQR) | 29 | (23–35) | < 0.001 | ||||
| 15–19, n (%) | 115 | (13) | 12 | (6) | 10 | (13) | |
| 20–24, n (%) | 174 | (20) | 19 | (10) | 10 | (14) | |
| 25–29, n (%) | 184 | (21) | 34 | (17) | 13 | (18) | |
| 30–34, n (%) | 188 | (21) | 61 | (31) | 20 | (27) | |
| 35–39, n (%) | 230 | (26) | 74 | (37) | 21 | (28) | |
| Treatment duration, mo. (median, IQR) | |||||||
| Anthracycline | 2 | (0.0 – 5.0) | - | 2 | (0.0 – 7.0) | 0.34 | |
| VEGF inhibitor | - | 3 | (0.0 – 9.0) | 2 | (0.0 – 5.0) | 0.04 | |
| Primary cancer diagnosis, n (%) | < 0.001 | ||||||
| Brain and spinal | 12 | (1) | 51 | (26) | 2 | (3) | |
| Leukemia | 303 | (34) | 1 | (1) | 19 | (26) | |
| Lymphoma | 305 | (34) | 2 | (0) | 0 | (0) | |
| Sarcoma | 122 | (14) | 31 | (16) | 26 | (35) | |
| Epithelial/melanoma | 134 | (15) | 104 | (52) | 10 | (14) | |
| Other solid/unspecified tumorsa | 15 | (2) | 11 | (6) | 17 | (23) | |
| Comorbidities prior to treatment, n (%) | |||||||
| Hypertension | 71 | (8) | 28 | (14) | 4 | (5) | 0.01 |
| Diabetes | 22 | (2) | 10 | (5) | 4 | (5) | 0.09 |
| Dyslipidemia | 36 | (4) | 11 | (6) | 4 | (5) | 0.60 |
| Tobacco smoking use, n (%) | 0.17 | ||||||
| Current | 57 | (6) | 12 | (6) | 5 | (7) | |
| Former | 69 | (8) | 34 | (17) | 10 | (14) | |
| Never | 765 | (86) | 154 | (77) | 59 | (80) | |
| Cardiovascular, n (%) | |||||||
| Peripheral arterial disease | 5 | (1) | 1 | (1) | 1 | (1) | 0.69 |
| Coronary disease | 1 | (0) | 0 | (0) | 0 | (0) | * |
| Cardiomyopathy/heart failure | 10 | (1) | 1 | (0) | 0 | (0) | * |
| Cerebrovascular disease | 1 | (0) | 0 | (0) | 2 | (3) | * |
| Charlson comorbidity index (median, IQR) | 0 | (0 – 1) | 1 | (0 – 1) | 0 | (0 – 1) | < 0.001 |
| Vital status, n (%) | < 0.001 | ||||||
| Alive at last follow-up | 613 | (69) | 87 | (43) | 16 | (22) | |
| Deceased | 278 | (31) | 113 | (57) | 58 | (78) | |
Categorical comparisons were made using chi-squared test. Continuous variables were not normally distributed and were compared using Kruskal–Wallis
*Unable to make accurate statistical comparison due to small sample sizes
aIncludes breast, gastrointestinal, reproductive, and pulmonary malignancies, as well as any malignancies not further specified